Systemic Immune-Inflammatory Index as a Prognostic Biomarker in Patients with Heart Failure: A Comprehensive Analysis

Area of Science:

• Cardiology
• Immunology
• Biomarker Discovery

Background:

• Chronic heart failure (CHF) poses a significant global health burden.
• Accurate prognostic biomarkers are crucial for managing CHF patients.
• The Systemic Immune-Inflammatory Index (SII) has emerged as a potential indicator of inflammation and prognosis.

Purpose of the Study:

• To evaluate the prognostic value of the Systemic Immune-Inflammatory Index (SII) in patients with chronic heart failure (CHF).
• To determine if SII can serve as an independent predictive biomarker for adverse outcomes in CHF.

Main Methods:

• Retrospective analysis of 2748 CHF patients.
• Data collected from 2012 to 2022.
• Primary endpoint: all-cause mortality (ACM); Secondary endpoint: readmission rates.
• Optimal SII cutoff value determined for ACM prediction.

Main Results:

• Elevated SII levels were significantly associated with increased risk of ACM in CHF patients.
• The high SII group demonstrated a 43.8% higher risk of ACM compared to the low SII group.
• This association remained consistent across all left ventricular ejection fraction (LVEF) categories.

Conclusions:

• The Systemic Immune-Inflammatory Index (SII) is a valuable and independent prognostic biomarker in chronic heart failure (CHF).
• SII aids in risk stratification and clinical decision-making for CHF patients.
• Further prospective studies are warranted to confirm these findings.